Surgery risks have been highlighted in a new warning for users of popular diabetes and weight-loss drugs, including Ozempic ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

Insulin efsitora alfa (investigational once-weekly basal insulin): In another ADA-sponsored symposium, Lilly will share results from the QWINT-1, QWINT-3 and QWINT-4 Phase 3 trials, which evaluated ...

Trulicity (dulaglutide) is an injectable medication for treating type 2 diabetes. Some, but not all, Medicare Part D plans may cover Trulicity. One treatment option is an injectable medication ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...